Traxanox is a diuretic agent possessing an uricosuric effect in animals. The diuretic and uricosuric effects of the drug have also been demonstrated in normotensive healthy subjects. The chronic administration of traxanox reduces serum uric acid level as well as blood pressure in patients with mild to moderate hypertension. This reduction in serum uric acid is due in part to a traxanox-induced elevation of urinary uric acid excretion. Traxanox sodium stimulates the phagocytic activity of leukocytes or macrophages and prevents the drug-induced suppression of the phagocytic activity of these cells. Traxanox may be clinically effective in treating patients with nasal allergies. The mode of action of traxanox on inflammatory responses resembles that of D-penicillamine or levamisole, so that it may prove to be clinically effective in treating rheumatoid arthritis. Also, traxanox may be effective for the treatment of allergic bronchial asthma.